KRYS Krystal Biotech Inc

P/E 39.04
Forward P/E 46.73
Price/Sales 20.93
Beta 0.498
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 Krystal Biotech is trading 4.4% up today as it rebounds from a recent pullback

Krystal Biotech is trading at $379.41 (4.4% up) in after-hours trading, rebounding from a modest recent pullback. • The advance appears to be a continuation...

🔴 Krystal Biotech is trading 4.2% down today amid potential profit-taking

Krystal Biotech is trading 4.2% down at $355.55 today amid potential profit-taking following a strong multi-month rally. • No fresh company-specific news or...

Krystal Biotech Hits 52-Week High, Driven by Strong Earnings Beat

Krystal Biotech Hits 52-Week High, Driven by Strong Earnings Beat

Krystal Biotech shares reached a new 52-week high of $382.54 during Wednesday's trading session. The stock maintains significant upward momentum following...

🟢 KRYS is trading 4.3% up today amid ongoing bullish analyst sentiment and options interest

KRYS is trading 4.3% up today at $362.40 as the stock extends its recent rally to reach fresh highs this week. • The move occurs without any new, price-moving...

🔴 KRYS is trading 4.6% down today on profit-taking after a multi-day rally

KRYS is trading 4.6% down at $327.69 in pre-market as the stock pulls back from a strong multi-day run that saw shares climb from $318 to over $343. • The...

🟢 Krystal Biotech Inc is trading 4.8% up today as analysts upgrade targets and Vyjuvek sales drive strong performance

Krystal Biotech Inc is trading at $358.00 (+4.78%) in pre-market following recent positive developments. * Wall Street analysts, including Jefferies and...

🟢 Krystal Biotech Inc extends move to 5.3% up

KRYS is trading at $340.48, up 5.3% versus the comparison close of $323.37 during regular trading. This is a price-movement alert; no separate company-specific...

🟢 Krystal Biotech Inc is trading 4.2% up today after Q1 2026 earnings beat and Jefferies price target hike

Krystal Biotech Inc is trading at $336.98 (+4.21%) after reporting Q1 2026 financial results that surpassed analyst expectations and receiving a price target...